Page last checked
Weight loss · FDA-label results
The label does not publish an early-results date or a week-by-week forecast. It reports an average 13.6% change at 64 weeks for the daily tablet, 14.9% at 68 weeks for the 2.4 mg pen, and 18.8% at 72 weeks for the 7.2 mg pen in three separate trial groups.
Source: the current FDA label’s Studies 2, 7 and 8
The evidence clock
Some weeks show a dose change and others show a study result. They are not the same thing. Week 16 has no weight result because the label does not publish one there.
−13.6% mean change with the 25 mg tablet
−14.9% mean change with the 2.4 mg pen
−18.8% at 7.2 mg · −15.5% at 2.4 mg
Three different products and study groups
Wegovy is now a weekly pen and a daily tablet, and the weekly pen has more than one maintenance strength. These are not interchangeable result claims. Each table keeps the form, dose, population, placebo arm and final visit attached to the number that produced it.
NCT03548935 · 1,961 people · 68 weeks
| Trial group | Average change | Lost at least 20% |
|---|---|---|
| Placebo | −2.4% | 1.7% |
| Wegovy 2.4 mg pen | −14.9% | 30.2% |
NCT05564117 · 307 people · 64 weeks
| Trial group | Average change | Lost at least 20% |
|---|---|---|
| Placebo | −2.4% | 3.1% |
| Wegovy 25 mg tablet | −13.6% | 27.9% |
NCT05646706 · 1,407 people · 72 weeks
| Trial group | Average change | Lost at least 20% |
|---|---|---|
| Placebo | −3.9% | 2.8% |
| Wegovy 2.4 mg pen | −15.5% | 32.3% |
| Wegovy 7.2 mg pen | −18.8% | 45.5% |
The questions people actually ask
The FDA label does not set one day or week when a person should notice a result. It shows the dose climb and later group endpoints, but those answer different questions. The first dose begins exposure; it does not create a promised visible-result date.
The label does not publish a one-month group mean for these three trials. Dividing a 64-, 68- or 72-week average into equal monthly pieces would invent a steady rate the trials did not report.
No. The 18.8% figure comes from the 7.2 mg arm of Study 8. The standard 2.4 mg arm in that same trial averaged 15.5%, and 7.2 mg is not the starting dose.
Only cautiously. The tablet and pen results came from separate trials with different durations and participants. Their numbers can be placed side by side, but the label did not randomize one shared group between the pill and pen.